Phoenix Financial Ltd. Has $4.14 Million Position in Abbott Laboratories $ABT

Phoenix Financial Ltd. decreased its stake in Abbott Laboratories (NYSE:ABT) by 20.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,906 shares of the healthcare product maker’s stock after selling 7,773 shares during the period. Phoenix Financial Ltd.’s holdings in Abbott Laboratories were worth $4,140,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new stake in shares of Abbott Laboratories in the 2nd quarter valued at approximately $3,026,180,000. Laurel Wealth Advisors LLC raised its position in Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after acquiring an additional 6,011,891 shares in the last quarter. Vanguard Group Inc. lifted its stake in Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after acquiring an additional 2,977,715 shares during the last quarter. First Trust Advisors LP grew its position in shares of Abbott Laboratories by 180.7% in the 2nd quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after acquiring an additional 1,972,097 shares during the period. Finally, TD Asset Management Inc raised its holdings in shares of Abbott Laboratories by 98.6% in the 2nd quarter. TD Asset Management Inc now owns 3,467,896 shares of the healthcare product maker’s stock valued at $471,669,000 after purchasing an additional 1,721,523 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of several research analyst reports. BTIG Research dropped their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Citigroup cut their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Evercore ISI decreased their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Finally, Jefferies Financial Group increased their price target on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $140.79.

Abbott Laboratories Trading Down 0.5%

Shares of NYSE:ABT opened at $108.22 on Wednesday. The company has a market capitalization of $188.18 billion, a P/E ratio of 29.09, a P/E/G ratio of 1.73 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The business’s 50 day simple moving average is $123.90 and its 200 day simple moving average is $127.95. Abbott Laboratories has a 1 year low of $105.78 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the firm earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.